Posted on 21/10/2009 in Pharmaceutical Company Product News GlaxoSmithKline drug Votrient (pazopanib) - which is intended for use in patients with renal cell carcinoma (RCC) - has been approved by the Food and Drug Administration (FDA).
Votrient is a once-daily oral medication and an angiogenesis inhibitor that may help prevent the growth of new blood vessels, contributing to the hindering of kidney cancer tumors' growth.
The FDA's decision comes after a phase III clinical trial showed that Votrient reduces the risk of tumour progression or death by 54 per cent compared to a placebo, regardless of prior treatment.
Paolo Paoletti, senior vice-president of GlaxoSmithKline's oncology research and development unit, explained that RCC is "highly resistant" to chemotherapy.
"Votrient will join existing targeted therapies to provide physicians with a new oral treatment option to their patients with advanced renal cell cancer," he added.
GlaxoSmithKline this week announced that it will join forces with the Holland-based biopharmaceutical firm Prosensa to develop and commercialise therapies for Duchenne muscular dystrophy.
Other news stories from 21/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
